By Bhanvi Satija and Yadarisa Shabong LONDON, June 9 (Reuters) – GSK has agreed to buy U.S.-listed cancer drug developer Nuvalent for $10.6 billion in its largest deal in more than a decade, marking a
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Exclusive-Vietnam's first chip plant unlikely to meet 2027 target, sources say no deal yet with ASML
By Francesco Guarascio, Khanh Vu and Toby Sterling HANOI/AMSTERDAM, Oct 26 (Reuters) - Vietnam is…
Audi CEO's appearance at Trump rally was 'deeply embarrassing', IG Metall head says
FRANKFURT, Oct 26 (Reuters) - The head of Germany's biggest trade union IG Metall and…
Apollo Micro Systems Q2 Profit Jumps 54%, Revenue Rises 72% to Rs 388 Crore
New Delhi [India], October 26: Apollo Micro Systems Ltd, a defence electronics and technology company,…
